Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,915 | 1,000 | 06.06. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
30.05. | RECBIO-B (02179): FORM OF PROXY FOR USE AT THE 2024 ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 20, 2025 | 2 | HKEx | ||
30.05. | RECBIO-B (02179): NOTICE OF 2024 ANNUAL GENERAL MEETING | 1 | HKEx | ||
30.05. | RECBIO-B (02179): CIRCULAR OF 2024 ANNUAL GENERAL MEETING | - | HKEx | ||
21.05. | RECBIO-B (02179): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
21.05. | RECBIO-B (02179): PROPOSED PARTICIPATION IN THE H SHARE FULL CIRCULATION PLAN BY THE COMPANY, PROPOSED CHANGES IN BUSINESS SCOPE, PROPOSED AMENDMENTS ... | - | HKEx | ||
22.04. | RECBIO-B (02179): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
22.04. | RECBIO-B (02179): 2024 ANNUAL REPORT | - | HKEx | ||
JIANGSU RECBIO TECHNOLOGY Aktie jetzt für 0€ handeln | |||||
28.03. | RECBIO-B (02179): UPDATE ON THE QUALIFICATION OF THE JOINT COMPANY SECRETARY | 1 | HKEx | ||
28.03. | RECBIO-B (02179): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024 AND PROPOSED APPOINTMENT OF THE BOARD OBSERVER | - | HKEx | ||
18.03. | RECBIO-B (02179): DATE OF BOARD MEETING | - | HKEx | ||
27.02. | RECBIO-B (02179): ANNOUNCEMENT IN RELATION TO THE ACCEPTANCE BY THE CSRC OF THE APPLICATION MATERIALS FOR THE ISSUANCE OF DOMESTIC SHARES | 2 | HKEx | ||
12.02. | RECBIO-B (02179): VOLUNTARY ANNOUNCEMENT ACCEPTANCE OF THE APPLICATION FOR CLINICAL TRIAL OF THE COMPANY'S NOVEL ADJUVANTED RECOMBINANT HPV 9-VALENT ... | - | HKEx | ||
09.01. | RECBIO-B (02179): CORRIGENDUM OF POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON DECEMBER 24, 2024 | 3 | HKEx | ||
02.01. | RECBIO-B (02179): VOLUNTARY ANNOUNCEMENT COMPLETION OF ENROLLMENT OF PHASE III CLINICAL TRIAL OF THE COMPANY'S NOVEL ADJUVANTED RECOMBINANT SHINGLES ... | 1 | HKEx | ||
24.12.24 | RECBIO-B (02179): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON DECEMBER 24, 2024 | 1 | HKEx | ||
25.07.24 | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 25.07.2024 | 243 | Xetra Newsboard | The following instruments on XETRA do have their first trading 25.07.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 25.07.2024
Aktien
1 US55607P2048 Macquarie Group Ltd.... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PHATHOM PHARMACEUTICALS | 8,920 | +90,19 % | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | ||
AVIDITY BIOSCIENCES | 36,240 | +1,83 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
QIAGEN | 40,060 | -0,55 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
ARCELLX | 68,10 | +2,81 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 14,370 | +6,37 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
RECURSION PHARMACEUTICALS | 5,485 | +20,02 % | Recursion Pharmaceuticals shares surge on AI model release | ||
TARSUS PHARMACEUTICALS | 43,920 | -0,39 % | Oppenheimer assumes Tarsus stock at outperform on strong sales | ||
BIONTECH | 95,35 | +0,05 % | Summit Therapeutics crasht - BioNTech in Sippenhaft | Wie gewonnen, so zerronnen: Die Aktie von Summit Therapeutics brach am vergangenen Freitag an der Nasdaq um rund 30 Prozent ein. Weitere Studiendaten zum großen Hoffnungsträger Ivonescimab, den die... ► Artikel lesen | |
VERA THERAPEUTICS | 22,760 | -25,69 % | Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy | Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 46,880 | -3,99 % | ROUNDUP/Aktien New York: Knappes Plus - Gelassenheit trotz Zoll-Unruhen | NEW YORK (dpa-AFX) - Die US-Börsen haben am Dienstag knappe Kursgewinne erzielt. Die jüngst wieder aufflackernden, internationalen Handelsstreitigkeiten wegen der amerikanischen Zollpolitik scheinen... ► Artikel lesen | |
EDGEWISE THERAPEUTICS | 15,240 | +2,83 % | RBC Capital behält Outperform-Rating für Edgewise Therapeutics-Aktie bei | ||
JANUX THERAPEUTICS | 26,210 | +5,86 % | Leerink cuts Janux Therapeutics price target to $89, keeps Outperform | ||
EVOTEC | 7,060 | +0,94 % | Evotec Aktie: Ohne Übernahme sieht es schlecht aus! Auf diese Kursmarke kommt es an! | © Foto: Finanznachrichten (Symbolbild)Zwischen Kursrakete mit Übernahmefantasie und Korrekturmodus Richtung Süden. Der Biotech-Titel aus Hamburg liefert seit Wochen ein Wechselbad der Gefühle. Kann... ► Artikel lesen | |
89BIO | 10,250 | +3,12 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
TREVI THERAPEUTICS | 7,060 | +4,75 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough | Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p
Patients saw a... ► Artikel lesen |